GIGABYTE-TECHNOLOGY
4.6.2021 11:38:50 CEST | Business Wire | Press release
GIGABYTE Technology, a leading brand of computer innovations, continues its strong presence at COMPUTEX, joining the “#COMPUTEXVirtual” platform as the exhibition takes place online due to global pandemic situation. From May 31st to June 30th , GIGABYTE orchestrated 10 different sections in a dedicated “GIGABYTE Pavilion” to exhibit a series of products and solutions that can expand on its “Bring Smart to Life” concept, from the data center to personal computer, and 5G to edge AI computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210604005208/en/
GIGABYTE is known for having the most extensive portfolio of AMD servers for demanding workloads, and has readied a comprehensive lineup of servers supporting the 7nm processor, unlocking its incredible performance of up to 64 cores and 128 threads to enable developers and scientists to tackle challenges in HPC and cloud computing. Correspondingly, GIGABYTE is primed to present Intel servers based on the latest 3rd Gen. Intel® Xeon® Scalable Processors suited for enterprises looking to upgrade their IT infrastructure.
At the forefront of server development is an NVIDIA Arm HPC Developer Kit, a system that includes an Ampere Altra processor, two NVIDIA A100 Tensor Core GPUs, and two NVIDIA BlueField®-2 DPUs, all contained in a leading-edge GIGABYTE G242 server. In addition, GIGABYTE will present four ARM server products, all of which can leverage the power of the 80-core (250W) Ampere Altra processors to provide outstanding efficiency, performance, and throughput.
Smart cities benefited from the computing power of data centers through GIGABYTE’s industrial motherboards, embedded systems, automotive electronics, 3D depth sensing solutions, visual recognition solutions, and deep learning-based AI training and inferencing programs. Notable exhibits will include Industry 4.0 factory automation and smart retail solutions, in-vehicle ECU and AI edge computing platforms, and AI facial recognition systems.
PC consumers are treated with AORUS and AERO premium laptops, now powered by Intel’s latest 11th Gen Tiger Lake-H series processors, while pairing with the full-power RTX 30 series graphics cards and 4K OLED panels respectively; new AORUS 4K gaming monitors equipped with exclusive tactical game-enhancement features and HDMI 2.1-ready for full support of the new-gen gaming consoles; and two prebuilt AORUS flagship systems that are the world’s first factory-tuned gaming desktops, with the most powerful component to date, and tuned and tested to ensure impeccable stability and performance out of the box.
Visit “GIGABYTE Pavilion”
https://virtual.computextaipei.com.tw/area/gigabyte/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005208/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom